Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Fürth – page 11

543 clinical trials in Fürth, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Fürth at a glance
543
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

543 trials in Fürth

Open in trial search

Study comparing GSK5764227 and topotecan in adults with relapsed small cell lung cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:GSK5764227
  • Sponsor:Glaxosmithkline Research & Development Limited

Study of risankizumab safety and effectiveness in children and teenagers aged 2-17 years with moderate to severe ulcerative colitis

Investigational
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study of drug combination therapy after surgery in patients with resectable pancreatic ductal adenocarcinoma using lab-grown mini-tumors to guide treatment selection

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Universitaetsklinikum Ulm AöR

Study of loncastuximab tesirine and epcoritamab combination treatment for patients with relapsed or refractory diffuse large B-cell lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Epcoritamab
  • Sponsor:Universitaet Muenster

Breast cancer+1

Recruiting

Study of typology-based coaching and education to help patients with early hormone-positive HER2-negative breast cancer manage their treatment with ribociclib

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ribociclib
  • Sponsor:Institut Für Frauengesundheit GmbH

Study of sacituzumab tirumotecan, pembrolizumab and chemotherapy combination for early-stage triple-negative breast cancer or hormone receptor-low positive/HER2-negative breast cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Merck Sharp & Dohme LLC

Cardiomyopathy

Recruiting

Study of Nucresiran in Adults with Transthyretin Amyloidosis with Cardiomyopathy to Evaluate its Effects on Survival and Heart Problems

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Nucresiran
  • Sponsor:Alnylam Pharmaceuticals Inc.

Neuroblastoma+3

Recruiting

Long-term safety study of GD2IL18CART treatment in patients with neuroblastoma, osteosarcoma, Ewing sarcoma, or advanced breast cancer

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:GD2IL18CART
  • Sponsor:Universitaet Muenster

Study of drug combination therapy for prevention of recurrent stroke in patients with acute ischemic stroke and atrial fibrillation

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Flecainide Acetate
  • Sponsor:University Medical Center Hamburg-Eppendorf

Study of patritumab deruxtecan versus drug combination in patients with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Merck Sharp & Dohme LLC

Study of Rilvegostomig with Bevacizumab and Tremelimumab as First-line Treatment for Patients with Advanced Liver Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:AstraZeneca AB

Evaluating sacituzumab tirumotecan alone or with pembrolizumab compared to standard treatment in untreated patients with metastatic triple-negative breast cancer with low PD-L1 expression

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Fürth

What the registry says about research in the country

01 Breast Cancer Research

Innovative studies focusing on triple-negative breast cancer and HER2-negative variants, exploring new therapeutic approaches with targeted treatments.

  • Advanced treatment combinations
  • Maintenance therapy evaluation
  • Genetic mutation targeting

Multiple trials investigating novel drug combinations for improving patient outcomes.

02 Gastrointestinal Oncology

Research centered on colorectal cancer treatment, including studies for both early-stage and metastatic disease management.

  • Post-resection therapy optimization
  • Circulating tumor DNA analysis
  • Stage II cancer interventions

Examining innovative approaches to improve survival rates in colorectal cancer patients.

03 Cardiovascular Medicine

Studies addressing myocardial infarction and complex cardiac conditions, with emphasis on innovative therapeutic strategies.

  • STEMI treatment protocols
  • Anticoagulation management
  • Post-stent therapy optimization

Investigating new treatments for improved cardiac outcomes and reduced mortality rates.

04 Gynecologic Oncology

Advanced research in ovarian cancer treatment, focusing on maintenance therapy after initial treatment response.

  • Platinum-based therapy enhancement
  • Progression-free survival studies
  • Stage III/IV cancer management

Evaluating innovative maintenance treatments for advanced ovarian cancer patients.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.